Syed Zaidi, MD
Nephrology · Conroe, TXNPI 1912090572
Payments from drug & device makers
What this record shows
This record is dominated by grants: $15,000 of the $18,817 with a category attached, or 79.7%. Boston Scientific accounts for 82.3% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2024 at $15,735 and has fallen 89.3% since, to $1,689 in 2025. Among nephrology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 155 payments — averaging $121.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$15K
- AstraZeneca$562
- Amgen$384
- Otsuka America Pharmaceutical, Inc.$331
- Calliditas Therapeutics US Inc.$272
- Travere Therapeutics, Inc.$234
- plus $2K from 20 others
Across 2 payments — averaging $2893.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$6K
What the payments were for
- Grants$15,00080%
- Food & beverage$3,81720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 4 | $15,489 |
| AstraZeneca | 29 | $562 |
| Amgen(2 entities) | 19 | $384 |
| Otsuka America Pharmaceutical, Inc. | 15 | $331 |
| Calliditas Therapeutics US Inc. | 12 | $272 |
| Travere Therapeutics, Inc. | 9 | $234 |
| GSK | 9 | $206 |
| Novartis | 7 | $160 |
| Stryker | 1 | $153 |
| Mallinckrodt Hospital Products Inc. | 6 | $147 |
| Bayer | 8 | $145 |
| Lilly USA, LLC | 7 | $134 |
| Novo Nordisk | 6 | $131 |
| Recor Medical Inc | 4 | $82 |
| Ardelyx, Inc. | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $49 |
| Vifor Pharma, Inc. | 3 | $45 |
| Fresenius USA Marketing, Inc. | 1 | $36 |
| Akebia Therapeutics Inc | 2 | $35 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $35 |
| OPKO Pharmaceuticals, LLC | 2 | $31 |
| Aurinia Pharma U.S., Inc. | 1 | $27 |
| Ascendis Pharma Endocrinology Inc | 1 | $25 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Boehringer Ingelheim | 1 | $15 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,817 in reported general payments places this provider in the 90th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 176 | $187,154 |
| FilspariSparsentan | 11 | $120,018 |
| KerendiaFinerenone | 85 | $77,883 |
| JardianceEmpagliflozin | 19 | $31,894 |
| VeltassaPatiromer Calcium Sorbitex | 22 | $29,124 |
| ProcritEpoetin Alfa | 15 | $17,050 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $14,523 |
| Bumetanide | 133 | $7,584 |
| Sevelamer Carbonate | 33 | $7,172 |
| Cinacalcet Hcl | 22 | $6,212 |
| Potassium Chloride | 65 | $4,526 |
| Nifedipine ErNifedipine | 94 | $3,933 |
| Calcium Acetate | 26 | $2,457 |
| Potassium Citrate ErPotassium Citrate | 18 | $1,956 |
| Clonidine | 13 | $1,821 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $562 | $201,677188 claims |
| Travere Therapeutics, Inc.Filspari | $234 | $120,01811 claims |
| BayerKerendia | $145 | $77,88385 claims |
| Boehringer IngelheimJardiance | $15 | $31,89419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Conroe
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
- Anand ReddyOdessa$469K
- Christopher KwohHouston$467K
- Wolfgang WinkelmayerHouston$462K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.